COPD 발병률이 전 세계에서 증가하면서 만성폐쇄성폐질환의 보급을 촉진하고 있습니다. 젊은 층의 담배 소비 증가와 제네릭 의약품 사용에 대한 일반 대중의 인식이 높아짐에 따라 시장 규모는 2024년에 211억 7,000만 달러를 돌파하며, 2032년에는 약 353억 달러의 평가액에 달할 전망입니다.
이와 더불어, 신흥 국가의 의료비 지출이 증가하면서 만성폐쇄성폐질환 치료에 박차를 가하고 있습니다. 정부 및 대기업의 R&D 투자 확대는 2026-2032년 CAGR 7.28% 시장 성장을 가능하게 하고 있습니다.
만성폐쇄성폐질환 시장 정의/개요
만성폐쇄성폐질환(COPD)은 폐기종, 만성기관지염으로도 알려져 있으며, 기류 제한과 호흡 장애를 유발하는 폐질환입니다. 증상으로는 기침, 호흡곤란, 천명, 천명음, 피로감 등이 있습니다. 일반적인 원인으로는 흡연과 대기 오염이 있으며, COPD 환자는 다른 건강 문제의 위험이 높습니다. 만성 기관지염은 기관지에 염증을 일으켜 부종과 점액 축적을 일으켜 기관지 입구가 좁아져 공기가 폐로 들어오고 나가는 것을 어렵게 만듭니다. 폐기종은 폐의 바닥에 있는 기낭(폐포)이 파괴된 것으로 기관을 줄기, 기관지를 가지, 기낭을 잎사귀로 비유하면 거꾸로된 나무와 같습니다.
만성폐쇄성폐질환(COPD)의 치료는 증상 완화, 삶의 질 개선, 질병의 진행을 늦추는 데 중점을 두고 있습니다. 기도 근육을 이완시켜 기류를 개선하는 기관지확장제, 염증을 억제하는 흡입용 코르티코스테로이드, 효과를 높이는 흡입제의 병용 등이 주요 내용입니다. 운동 훈련, 영양 상담, 교육을 포함한 폐 재활 프로그램은 환자의 역량 강화와 기능 개선을 위해 매우 중요합니다. 심한 경우에는 산소 보충 요법이 필요할 수도 있습니다. 또한 질병의 진행을 막기 위해서는 금연이 필수적이며, 백신 접종과 정기적인 모니터링은 악화를 예방하고 동반 질환을 효과적으로 관리하는데 도움이 됩니다.
COPD 치료의 미래는 맞춤형 의료, 첨단 약물전달 시스템, 혁신적인 치료법에 초점이 맞추어질 것으로 보입니다. 주요 동향으로는 특정 염증 경로를 표적으로 하는 생물제제, 폐 조직 회복을 위한 유전자 치료 및 재생의료, 원격의료 및 원격 모니터링과 같은 디지털 헬스 기술, 새로운 흡입기 기술 및 약물 제제 등을 들 수 있습니다. 이러한 발전은 COPD 환자의 예후와 삶의 질을 개선하고, 환자 관리와 치료 계획 준수를 강화하는 것을 목표로 하고 있습니다.
만성폐쇄성폐질환(COPD)에 대한 인식이 높아짐에 따라 전 세계에서 진단 및 인지도가 향상되고 있습니다. 의료 전문가와 일반인 사이에서 이러한 인식 증가는 COPD를 조기에 발견하여 적시에 개입하고 더 나은 관리 전략을 수립하는 데 매우 중요합니다. 이에 따라 진단 툴의 개선, 보다 효과적인 치료법, COPD에 대한 이해와 대책을 위한 연구에 대한 요구가 증가하고 있습니다. 이러한 상황의 변화는 COPD가 개인과 의료 시스템에 미치는 영향을 줄이기 위한 교육과 적극적인 헬스케어 구상의 중요성을 강조하며 시장 성장을 가속하고 있습니다.
세계에서 COPD 환자 증가는 공중보건의 심각한 문제이며, 그 원인 중 하나는 여전히 COPD의 주요 위험요인인 흡연입니다. 전 세계에서 성인 흡연율이 증가함에 따라 COPD의 부담이 증가하고 있으며, 이는 종합적인 금연 프로그램과 담배 규제 강화가 시급하다는 것을 강조하고 있습니다. 또한 오염물질에 대한 직업적 노출과 실내 공기 오염은 COPD 발병 위험을 더욱 악화시키고 있습니다. 이러한 환경적 요인을 규제 및 작업장 개입을 통해 해결하는 것은 COPD의 발병과 진행을 억제하여 환자의 삶의 질을 개선하고 의료 자원에 대한 부담을 줄이는 데 매우 중요합니다.
폐활량 측정, CT 스캔, 바이오마커 검사 등 진단 기술의 발전으로 만성폐쇄성폐질환(COPD)의 관리가 크게 개선되었습니다. 이러한 기술들은 조기 발견, 맞춤형 치료 계획, 증상 조절을 개선하는 데 도움을 줍니다. 또한 기관지확장제, 코르티코스테로이드, 생물제제 등의 치료 옵션은 COPD 환자의 삶의 질을 향상시키고 있습니다. 예를 들어 2021년 2월 사노피와 리제네론 파마슈티컬스(Regeneron Pharmaceuticals)는 이테페키맙의 COPD 급성 악화를 억제하는 이테페키맙의 효능과 안전성을 평가하기 위한 임상 3상 시험을 진행 중이며, 시험 종료는 2024년 7월로 예정되어 있습니다.
National Center for BIoTechnology Information에 따르면 만성폐쇄성폐질환(COPD) 치료에 사용되는 약물의 부작용 증가는 시장 성장을 크게 저해하고 있으며, 흡입 스테로이드와 같은 약물은 구강 감염, 타박상, 쉰 목소리 등을 유발할 수 있다고 합니다. 환자의 순응도를 저해하고 시장 확대를 제한할 수 있습니다. 또한 이러한 약물을 사용하는 COPD 환자는 독감, 감기, 폐렴과 같은 호흡기 감염에 걸리기 쉬워 치료를 더욱 복잡하게 만들고 의료비용을 증가시킵니다.
또한 COPD의 복잡성과 치료에 대한 환자 반응의 다양성으로 인해 약물 개발이 특히 어려운 상황입니다. 임상 2상 시험인 TERRANOVA 검사나 GALATHEA 검사와 같은 임상시험은 유효성과 안전성을 입증하는 데 어려움을 겪고 있으며, COPD 시장의 발전을 더욱 저해하고 있습니다. 이러한 의약품 개발의 불확실성은 투자를 억제하고 새로운 치료법의 도입을 지연시킵니다.
COPD 신약 개발은 높은 임상시험 실패율 등 여러 가지 난제가 산적해 있습니다. 예를 들어 2019년 5월 천식 치료제인 벤라리주맙은 중등도에서 중증 COPD 환자의 연간 COPD 악화율을 낮추지 못했습니다. 이러한 좌절은 효과적인 치료법 발견의 어려움을 강조하며 시장 성장 전망을 제한하고 있습니다.
우울증, 심장병, 폐동맥 고혈압, 폐암 등 COPD에 수반되는 합병증 또한 효과적인 관리와 시장 성장의 과제입니다. 이러한 합병증의 심각성은 종합적인 치료 접근이 필요하지만, 비용과 자원이 많이 소요되는 경우가 많아 시장 성장을 저해하는 요인으로 작용하고 있습니다.
Rising incidence of COPD among populations across the globe is propelling the adoption of chronic obstructive pulmonary disease. The increasing tobacco consumption among young people & rising public awareness of the usage of generic drugs is driving the market size surpass USD 21.17 Billion valued in 2024 to reach a valuation of around USD 35.3 Billion by 2032.
In addition to this, increasing expenditure on healthcare is giving services in emerging countries is spurring up the adoption of chronic obstructive pulmonary disease. Growing R&D investment by the government and large players is enabling the market grow at a CAGR of 7.28% from 2026 to 2032.
Chronic Obstructive Pulmonary Disease Market: Definition/ Overview
Chronic obstructive pulmonary disease (COPD), also known as emphysema or chronic bronchitis, is a lung disease causing restricted airflow and breathing issues. Symptoms include cough, difficulty breathing, wheezing, and tiredness. Common causes include smoking and air pollution, and those with COPD are at higher risk of other health issues. Chronic bronchitis causes inflammation of the bronchial tubes, causing swelling and the buildup of mucus, which narrows the tube's opening, making it difficult for air to enter and exit the lungs. Emphysema is the breakdown of air sacs (alveoli) at the bottom of the lung, similar to an upside-down tree with the windpipe as the trunk, bronchi as branches, and air sacs as leaves.
Chronic Obstructive Pulmonary Disease (COPD) treatment focuses on alleviating symptoms, improving quality of life, and slowing disease progression. Key components include bronchodilators to relax airway muscles and improve airflow, inhaled corticosteroids to reduce inflammation, and combination inhalers for enhanced efficacy. Pulmonary rehabilitation programs, encompassing exercise training, nutrition advice, and education, are crucial for patient empowerment and functional improvement. Supplemental oxygen therapy may be necessary for severe cases. Additionally, smoking cessation is vital to halt disease progression, while vaccinations and regular monitoring help prevent exacerbations and manage comorbidities effectively.
The future of COPD treatment will focus on personalized medicine, advanced drug delivery systems, and innovative therapies. Key trends include biologics targeting specific inflammatory pathways, gene therapy and regenerative medicine for lung tissue repair, digital health technologies like telemedicine and remote monitoring, and novel inhaler technologies and drug formulations. These advancements aim to improve outcomes and quality of life for COPD patients, enhancing patient management and adherence to treatment plans.
Rising awareness of chronic obstructive pulmonary disease (COPD) continue to advance, there is a corresponding increase in the diagnosis and recognition of the condition globally. This heightened awareness among healthcare professionals and the public is crucial in identifying COPD at earlier stages, allowing for timely interventions and better management strategies. Consequently, there is a growing demand for improved diagnostic tools, more effective treatments, and increased research efforts aimed at understanding and combating COPD. This evolving landscape underscores the importance of education and proactive healthcare initiatives to mitigate the impact of COPD on individuals and healthcare systems, this is bolstering the growth of the market.
The rise in COPD cases globally presents a significant public health challenge, driven in part by factors such as tobacco smoking, which remains a leading risk factor for the disease. The increasing prevalence of adult smoking worldwide has contributed to a higher burden of COPD, highlighting the urgent need for comprehensive smoking cessation programs and stricter tobacco control measures. Additionally, occupational exposures to pollutants and indoor air pollution further exacerbate the risk of developing COPD. Addressing these environmental factors through regulatory policies and workplace interventions is crucial in reducing the incidence and progression of COPD, thereby improving the quality of life for affected individuals and lessening the strain on healthcare resources.
Advancements in diagnostic technologies like spirometry, CT scans, and biomarker testing have significantly improved the management of Chronic Obstructive Pulmonary Disease (COPD). These technologies enable early identification, personalized treatment plans, and improved symptom control. Additionally, therapeutic options like bronchodilators, corticosteroids, and biologic medicines have enhanced the quality of life for COPD patients. For instance, in February 2021, Sanofi and Regeneron Pharmaceuticals are conducting a Phase III clinical trial to evaluate the effectiveness and safety of itepekimab in reducing acute COPD exacerbations in former smokers, with the trial set to conclude in July 2024.
The rising side effects of drugs used in treating Chronic Obstructive Pulmonary Disease (COPD) significantly hinder market growth. According to the National Center for Biotechnology Information, medications such as inhaled steroids can cause oral infections, bruising, and hoarseness, which deter patient compliance and limit market expansion. Additionally, COPD patients on these medications are prone to respiratory infections like flu, colds, and pneumonia, further complicating their treatment and increasing healthcare costs.
Moreover, the complexity of COPD and the variability in patient response to treatments make drug development particularly challenging. Clinical trials, such as the Phase II TERRANOVA and GALATHEA studies, often struggle to demonstrate efficacy and safety, further impeding progress in the COPD market. This uncertainty in drug development discourages investment and slows the introduction of new therapies.
The development of new drugs for COPD is fraught with challenges, including high failure rates in clinical trials. For instance, in May 2019, benralizumab, an asthma drug, failed to reduce annual COPD exacerbation rates in patients with moderate to very severe COPD. Such setbacks highlight the difficulties in discovering effective treatments, limiting market growth prospects.
Complications associated with COPD, including depression, heart problems, high blood pressure in lung arteries, and lung cancer, also pose challenges to effective management and market growth. The severity of these complications necessitates comprehensive treatment approaches, which are often costly and resource-intensive, restraining market growth.
The drugs segment dominates the chronic obstructive pulmonary disease (COPD) market, primarily due to the widespread use of bronchodilators. Bronchodilators, both short-acting and long-acting, hold a largest market share. They are crucial for managing COPD symptoms by relaxing airways and providing rapid relief from bronchospasms and exacerbations. The inhaled delivery method enhances patient compliance, making them a preferred choice for both patients and healthcare providers. As COPD progresses and lung function declines, bronchodilators become even more significant in managing symptoms and preventing exacerbations.
Corticosteroids are essential COPD drugs that reduce airway inflammation and mucus production. They are often used in combination with bronchodilators, particularly in severe COPD patients or those with frequent exacerbations. They help alleviate symptoms and improve lung function over time, but long-term use may have potential side effects, requiring careful healthcare management.
Phosphodiesterase type 4 (PDE4) inhibitors represent a newer addition to COPD treatment options. These medications work by reducing inflammation and relaxing the airways, similar to corticosteroids but through a different mechanism. PDE4 inhibitors are typically prescribed for patients with severe COPD and a history of exacerbations despite bronchodilator and corticosteroid therapy. Their role in managing COPD involves improving lung function and reducing exacerbation frequency, contributing to overall disease control and patient well-being.
The COPD market comprises various drug classes, including bronchodilators for immediate symptom relief, corticosteroids for inflammation management, and PDE4 inhibitors for symptom relief, each playing a crucial role in managing COPD symptoms and enhancing patient outcomes.
Hospitals dominate the chronic obstructive pulmonary disease (COPD) market, with specialized departments like pulmonology and respiratory therapy, and advanced diagnostic capabilities like pulmonary function tests and imaging, ensuring accurate diagnosis and disease monitoring.
Hospitals offer a multidisciplinary approach to COPD management, involving pulmonologists, respiratory therapists, nurses, and rehabilitation specialists. They provide comprehensive care, addressing both medical and supportive needs. They offer a range of COPD treatments, including bronchodilators, corticosteroids, oxygen therapy, and surgical interventions. Hospitals also participate in clinical trials for innovative therapies.
Hospitals provide 24/7 emergency services, crucial for COPD patients experiencing sudden exacerbations or respiratory distress. This accessibility ensures prompt medical intervention and reduces morbidity and mortality associated with severe COPD complications.
North America stands out as a dominant force in the global chronic obstructive pulmonary disease (COPD) market for several compelling reasons. The region boasts a high prevalence of COPD, attributed partly to historical smoking rates and environmental factors. This prevalence drives substantial demand for COPD treatments and healthcare services, making it a significant contributor to the market's size and growth.
North America benefits from advanced healthcare infrastructure and robust pharmaceutical industry capabilities. This infrastructure supports comprehensive diagnostic capabilities, including advanced imaging and pulmonary function tests, crucial for accurate COPD diagnosis and monitoring. Moreover, the region's strong research and development ecosystem fosters continuous innovation in COPD therapies, ensuring patients have access to cutting-edge treatments and medications.
Also, efforts to raise public awareness about public health and implement smoking cessation programs in countries such as the United States and Canada are aimed at reducing risk factors for COPD and improving early detection. These initiatives contribute to improved disease management and outcomes, further solidifying North America's position as a leader in the global COPD market.
Furthermore, healthcare policies and reimbursement frameworks in North America facilitate access to COPD treatments, including bronchodilators, corticosteroids, and biologics. This accessibility ensures that COPD patients receive timely and appropriate care, enhancing treatment adherence and overall health outcomes.
The Asia-Pacific region is expected to witness significant growth in the drugs segment of the chronic obstructive pulmonary disease (COPD) market during the forecast period due to the rising prevalence of COPD. Increasing air pollution and high smoking rates in countries like China and India contribute to a growing patient population, driving demand for effective treatments.
A rising prevalence of respiratory distress conditions is a major driver in the region. According to the World Health Organization (WHO), over 90% of COPD-related deaths occur in low and middle-income countries, highlighting the critical need for effective treatments in Asia-Pacific.
Moreover, the presence of a large aging population in the region, which is more susceptible to COPD, is fueling the demand for maintenance and rescue medications. This demographic trend is a key driver of market growth in the drugs segment.
Pharmaceutical companies are increasingly focusing on the Asia-Pacific market due to its high growth potential. Investments in local manufacturing and distribution networks, along with strategic partnerships, are expanding the availability and affordability of COPD drugs, thereby supporting market expansion in the region.
The competitive landscape of the chronic obstructive pulmonary disease (COPD) market is characterized by intense competition and rapid innovation. Companies are focusing on developing advanced drug formulations and delivery systems to improve patient outcomes and adherence. Strategic collaborations, mergers, and acquisitions are common as firms aim to expand their market presence and leverage synergistic capabilities. Additionally, substantial investments in research and development, along with an emphasis on personalized medicine and biologics, are driving the evolution of treatment options, making the market highly dynamic and competitive. Some of the prominent players operating in the chronic obstructive pulmonary disease market include:
AstraZeneca
Boehringer Ingelheim
GlaxoSmithKline (GSK)
Novartis
Merck & Co.
Pfizer
Teva Pharmaceuticals
Sanofi
Mylan
Chiesi Farmaceutici
Sunovion Pharmaceuticals
Orion Corporation
Cipla
Reddy's Laboratories
Vectura Group
Circassia Pharmaceuticals
Theravance Biopharma
Verona Pharma
Glenmark Pharmaceuticals
Pulmatrix
In January 2022, A phase 4 study comparing Yupelri (revefenacin) and Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD) is underway. The study assesses the safety of these two approved daily COPD maintenance treatments. Yupelri, a bronchodilator developed by Theravance Biopharma and Mylan, relaxes and widens lung airways, making breathing easier. It is available as an inhalable solution via a nebulizer.
In November 2021, AstraZeneca sold the rights to commercialize Tudorza (Eklira) and Duaklir to Swiss pharmaceutical business Covis Pharma Group for US$ 270 million. The products are intended for the treatment of chronic obstructive pulmonary disease (COPD).